Credit Suisse Takes Teva Rating To Neutral In Third Upgrade Of Day
December 15, 2017 at 13:12 PM EST
Credit Suisse analyst Vamil Divan upgraded earlier today Teva Pharmaceutical to Neutral from Underperform and raised his price target for the shares to $20.